

# Fernando J Martinez

List of PR Articles by Year  
in descending order

Source: [//exaly.com/author-pdf/3550550/publications.pdf](https://exaly.com/author-pdf/3550550/publications.pdf)

Version: 2025-02-01

291

PR articles

40,742

PR citations

3520

79

PR h-index

1593

193

g-index

317

documents

49013

doc citations

4073

84

h-index

43425

citing authors

#	ARTICLE	IF	PR CITATIONS
1	Pulmonary Fibrosis Stakeholder Summit: A Joint NHLBI, Three Lakes Foundation, and Pulmonary Fibrosis Foundation Workshop Report. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2024, 209, 362-373.	12.2	12
2	Zinpentroxin Alfa for Idiopathic Pulmonary Fibrosis: The Randomized Phase III STARSCAPE Trial. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2024, 209, 1132-1140.	12.2	37
3	Association of urine mitochondrial DNA with clinical measures of COPD in the SPIROMICS cohort. <i>JCI Insight</i> , 2024, 9, .	5.4	0
4	COPD Exacerbations Before and During COVID-19 in France, Germany, Italy, the UK and the US. <i>International Journal of COPD</i> , 2024, Volume 19, 1433-1445.	2.8	4
5	RIOK2 transcriptionally regulates TRiC and dyskerin complexes to prevent telomere shortening. <i>Nature Communications</i> , 2024, 15, .	13.9	4
6	Systemic sclerosis associated interstitial lung disease: a conceptual framework for subclinical, clinical and progressive disease. <i>Rheumatology</i> , 2023, 62, 1877-1886.	2.0	13
7	Clinical Efficacy among Patients with Chronic Rhinosinusitis with Nasal Polyps and Clinical Features of Obstructive Lung Disease: Post Hoc Analysis of the Phase III SINUS-24 and SINUS-52 Studies. <i>Journal of Asthma and Allergy</i> , 2023, Volume 16, 333-342.	2.8	5
8	High versus Medium Dose of Inhaled Corticosteroid in Chronic Obstructive Lung Disease: A Systematic Review and Meta-Analysis. <i>International Journal of COPD</i> , 2023, Volume 18, 469-482.	2.8	8
9	Validity and Reliability of the Fatigue Severity Scale in a Real-World Interstitial Lung Disease Cohort. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2023, 208, 188-195.	12.2	21
10	Icenticaftor, a CFTR Potentiator, in COPD: A Multicenter, Parallel-Group, Double-Blind Clinical Trial. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2023, 208, 417-427.	12.2	34
11	Repeatability of Pulmonary Quantitative Computed Tomography Measurements in Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2023, 208, 657-665.	12.2	27
12	Approach to Clinical Trials for the Prevention of Pulmonary Fibrosis. <i>Annals of the American Thoracic Society</i> , 2023, 20, 1683-1693.	3.8	8
13	Treatment Trials in Young Patients with Chronic Obstructive Pulmonary Disease and Pre-“Chronic Obstructive Pulmonary Disease Patients: Time to Move Forward. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2022, 205, 275-287.	12.2	147
14	Alpha-1 Antitrypsin MZ Heterozygosity Is an Endotype of Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2022, 205, 313-323.	12.2	39
15	Significance of FEV3/FEV6 in Recognition of Early Airway Disease in Smokers at Risk of Development of COPD. <i>Chest</i> , 2022, 161, 949-959.	1.1	25
16	Long-Term Safety and Efficacy of Tocilizumab in Early Systemic Sclerosis-“Interstitial Lung Disease: Open-Label Extension of a Phase 3 Randomized Controlled Trial. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2022, 205, 674-684.	12.2	106
17	Cystic Fibrosis Transmembrane Conductance Regulator: Roles in Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2022, 205, 631-640.	12.2	28
18	Forced Expiratory Flow at 25%-75% Links COPD Physiology to Emphysema and Disease Severity in the SPIROMICS Cohort. <i>Chronic Obstructive Pulmonary Diseases (Miami, Fla)</i> , 2022, 9, 111-121.	0.9	14

#	ARTICLE	IF	PR CITATIONS
19	Phase 2B Study of Inhaled RVT-1601 for Chronic Cough in Idiopathic Pulmonary Fibrosis: A Multicenter, Randomized, Placebo-controlled Study (SCENIC Trial). American Journal of Respiratory and Critical Care Medicine, 2022, 205, 1084-1092.	12.2	20
20	CONQUEST: A Quality Improvement Program for Defining and Optimizing Standards of Care for Modifiable High-Risk COPD Patients. Patient Related Outcome Measures, 2022, Volume 13, 53-68.	1.7	5
21	Predictors of mortality in subjects with progressive fibrosing interstitial lung diseases. Respirology, 2022, 27, 294-300.	4.1	41
22	Integrating Clinical Probability into the Diagnostic Approach to Idiopathic Pulmonary Fibrosis: An International Working Group Perspective. American Journal of Respiratory and Critical Care Medicine, 2022, 206, 247-259.	12.2	24
23	Safety and tolerability of nintedanib in patients with progressive fibrosing interstitial lung diseases: data from the randomized controlled INBUILD trial. Respiratory Research, 2022, 23, .	4.5	40
24	International Differences in the Frequency of Chronic Obstructive Pulmonary Disease Exacerbations Reported in Three Clinical Trials. American Journal of Respiratory and Critical Care Medicine, 2022, 206, 25-33.	12.2	20
25	Ambient ozone effects on respiratory outcomes among smokers modified by neighborhood poverty: An analysis of SPIROMICS AIR. Science of the Total Environment, 2022, 829, 154694.	8.4	12
26	Lung tissue shows divergent gene expression between chronic obstructive pulmonary disease and idiopathic pulmonary fibrosis. Respiratory Research, 2022, 23, .	4.5	27
27	Rare and Common Variants in <i>KIF15</i> Contribute to Genetic Risk of Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2022, 206, 56-69.	12.2	50
28	Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. American Journal of Respiratory and Critical Care Medicine, 2022, 205, e18-e47.	12.2	2,189
29	Lung Microbiota and Metabolites Collectively Associate with Clinical Outcomes in Milder Stage Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2022, 206, 427-439.	12.2	76
30	Transbronchial Lung Cryobiopsy in Patients with Interstitial Lung Disease: A Systematic Review. Annals of the American Thoracic Society, 2022, 19, 1193-1202.	3.8	84
31	Reversible Airflow Obstruction Predicts Future Chronic Obstructive Pulmonary Disease Development in the SPIROMICS Cohort: An Observational Cohort Study. American Journal of Respiratory and Critical Care Medicine, 2022, 206, 554-562.	12.2	38
32	Relationship between prior inhaled corticosteroid use and benefits of budesonide/glycopyrronium/formoterol fumarate dihydrate on exacerbations, symptoms, health-related quality of life, and lung function in patients with chronic obstructive pulmonary disease: Analyses from the ETHOS study. Respiratory Medicine, 2022, 197, 106857.	2.8	14
33	Risk of COPD exacerbation is increased by poor sleep quality and modified by social adversity. Sleep, 2022, 45, .	1.0	19
34	Blood Eosinophils and Chronic Obstructive Pulmonary Disease: A Global Initiative for Chronic Obstructive Lung Disease Science Committee 2022 Review. American Journal of Respiratory and Critical Care Medicine, 2022, 206, 17-24.	12.2	126
35	Predictive modeling of COPD exacerbation rates using baseline risk factors. Therapeutic Advances in Respiratory Disease, 2022, 16, .	2.8	23
36	A Phase IIb Randomized Clinical Study of an Anti- $\alpha$ -1 $\pm$ Monoclonal Antibody in Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2022, 206, 1128-1139.	12.2	78

#	ARTICLE	IF	PR CITATIONS
37	Prevalence and Mechanisms of Mucus Accumulation in COVID-19 Lung Disease. American Journal of Respiratory and Critical Care Medicine, 2022, 206, 1336-1352.	12.2	62
38	Pharmacotherapy and Mortality in Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2022, 206, 1201-1207.	12.2	14
39	Single-Inhaler Triple Therapy in Patients with Advanced COPD: Bayesian Modeling of the Healthcare Resource Utilization Data and Associated Costs from the IMPACT Trial. International Journal of COPD, 2022, Volume 17, 1633-1642.	2.8	3
40	Utility of whole genome sequencing in assessing risk and clinically relevant outcomes for pulmonary fibrosis. European Respiratory Journal, 2022, 60, 2200577.	12.1	38
41	Single-inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol versus dual therapy in current and former smokers with COPD: IMPACT trial post hoc analysis. Respiratory Medicine, 2022, 205, 107040.	2.8	11
42	Benefits of Budesonide/Glycopyrronium/Formoterol Fumarate Dihydrate on COPD Exacerbations, Lung Function, Symptoms, and Quality of Life Across Blood Eosinophil Ranges: A Post-Hoc Analysis of Data from ETHOS. International Journal of COPD, 2022, Volume 17, 3061-3073.	2.8	20
43	Global Initiative for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease. The 2020 GOLD Science Committee Report on COVID-19 and Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2021, 203, 24-36.	12.2	628
44	Utility of a Molecular Classifier as a Complement to High-Resolution Computed Tomography to Identify Usual Interstitial Pneumonia. American Journal of Respiratory and Critical Care Medicine, 2021, 203, 211-220.	12.2	76
45	Effect of Age on the Efficacy and Safety of Once-Daily Single-Inhaler Triple-Therapy Fluticasone Furoate/Umeclidinium/Vilanterol in Patients With COPD. Chest, 2021, 159, 985-995.	1.1	8
46	Contribution of Individual and Neighborhood Factors to Racial Disparities in Respiratory Outcomes. American Journal of Respiratory and Critical Care Medicine, 2021, 203, 987-997.	12.2	64
47	Pharmacotherapy and Lung Function Decline in Patients with Chronic Obstructive Pulmonary Disease. A Systematic Review. American Journal of Respiratory and Critical Care Medicine, 2021, 203, 689-698.	12.2	73
48	Differential Responses to Targeting Matrix Metalloproteinase 9 in Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2021, 203, 458-470.	12.2	47
49	Mucus Plugs and Emphysema in the Pathophysiology of Airflow Obstruction and Hypoxemia in Smokers. American Journal of Respiratory and Critical Care Medicine, 2021, 203, 957-968.	12.2	150
50	Reduced All-Cause Mortality in the ETHOS Trial of Budesonide/Glycopyrrolate/Formoterol for Chronic Obstructive Pulmonary Disease. A Randomized, Double-Blind, Multicenter, Parallel-Group Study. American Journal of Respiratory and Critical Care Medicine, 2021, 203, 553-564.	12.2	228
51	Quantitative Emphysema on Low-Dose CT Imaging of the Chest and Risk of Lung Cancer and Airflow Obstruction. Chest, 2021, 159, 1812-1820.	1.1	60
52	Dual-combination maintenance inhaler preferences in asthma and chronic obstructive pulmonary disease: A patient-centered benefit-risk assessment. Respiratory Medicine, 2021, 176, 106278.	2.8	8
53	Prognostic value of clinically important deterioration in COPD: IMPACT trial analysis. ERJ Open Research, 2021, 7, 00663-2020.	2.6	12
54	Natural history and mechanisms of <scp>COPD</scp>. Respirology, 2021, 26, 298-321.	4.1	92

#	ARTICLE	IF	PR CITATIONS
55	Polycythemia is Associated with Lower Incidence of Severe COPD Exacerbations in the SPIROMICS Study. <i>Chronic Obstructive Pulmonary Diseases (Miami, Fla )</i> , 2021, 8, 326-335.	0.9	5
56	Budesonide/Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler Improves Exacerbation Outcomes in Patients with COPD without a Recent Exacerbation History: A Subgroup Analysis of KRONOS. <i>International Journal of COPD</i> , 2021, Volume 16, 179-189.	2.8	16
57	Lung microbiota associations with clinical features of COPD in the SPIROMICS cohort. <i>Npj Biofilms and Microbiomes</i> , 2021, 7, .	8.1	57
58	Blood Transcriptomics Predicts Progression of Pulmonary Fibrosis and Associated Natural Killer Cells. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021, 204, 197-208.	12.2	41
59	The influence of social support on COPD outcomes mediated by depression. <i>PLoS ONE</i> , 2021, 16, e0245478.	2.4	25
60	Latent traits of lung tissue patterns in former smokers derived by dual channel deep learning in computed tomography images. <i>Scientific Reports</i> , 2021, 11, .	3.5	15
61	InforMing the PATHway of COPD Treatment (IMPACT) trial: fibrinogen levels predict risk of moderate or severe exacerbations. <i>Respiratory Research</i> , 2021, 22, .	4.5	21
62	Association of plasma mitochondrial DNA with COPD severity and progression in the SPIROMICS cohort. <i>Respiratory Research</i> , 2021, 22, .	4.5	23
63	Genetic and non-genetic factors affecting the expression of COVID-19-relevant genes in the large airway epithelium. <i>Genome Medicine</i> , 2021, 13, .	9.7	34
64	Longitudinal Imaging-Based Clusters in Former Smokers of the COPD Cohort Associate with Clinical Characteristics: The SubPopulations and Intermediate Outcome Measures in COPD Study (SPIROMICS). <i>International Journal of COPD</i> , 2021, Volume 16, 1477-1496.	2.8	12
65	Airway mucin MUC5AC and MUC5B concentrations and the initiation and progression of chronic obstructive pulmonary disease: an analysis of the SPIROMICS cohort. <i>Lancet Respiratory Medicine</i> , the, 2021, 9, 1241-1254.	24.2	165
66	Challenging the obesity paradox: extreme obesity and COPD mortality in the SUMMIT trial. <i>ERJ Open Research</i> , 2021, 7, 00902-2020.	2.6	41
67	Treatment of Persistent Cough in Subjects with Idiopathic Pulmonary Fibrosis (IPF) with Gefapixant, a P2X3 Antagonist, in a Randomized, Placebo-Controlled Clinical Trial. <i>Pulmonary Therapy</i> , 2021, 7, 471-486.	2.8	41
68	Impact of lung morphology on clinical outcomes with riociguat in patients with pulmonary hypertension and idiopathic interstitial pneumonia: A post hoc subgroup analysis of the RISE-IIP study. <i>Journal of Heart and Lung Transplantation</i> , 2021, 40, 494-503.	1.2	29
69	Future concepts in bronchodilation for COPD: dual- <i>versus</i> monotherapy. <i>European Respiratory Review</i> , 2021, 30, 210023.	8.7	10
70	Reversal of emphysema by restoration of pulmonary endothelial cells. <i>Journal of Experimental Medicine</i> , 2021, 218, .	9.4	80
71	Ratio of FEV1/Slow Vital Capacity of &lt;math>0.7</math> Is Associated With Clinical, Functional, and Radiologic Features of Obstructive Lung Disease in Smokers With Preserved Lung Function. <i>Chest</i> , 2021, 160, 94-103.	1.1	15
72	Patient-centered Outcomes Research in Interstitial Lung Disease: An Official American Thoracic Society Research Statement. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021, 204, e3-e23.	12.2	77

#	ARTICLE	IF	PR CITATIONS
73	Identifying organ dysfunction trajectory-based subphenotypes in critically ill patients with COVID-19. <i>Scientific Reports</i> , 2021, 11, .	3.5	25
74	Benefits of budesonide/glycopyrrolate/formoterol fumarate (BGF) on symptoms and quality of life in patients with COPD in the ETHOS trial. <i>Respiratory Medicine</i> , 2021, 185, 106509.	2.8	19
75	Barriers to antigen detection and avoidance in chronic hypersensitivity pneumonitis in the United States. <i>Respiratory Research</i> , 2021, 22, .	4.5	18
76	CONQUEST Quality Standards: For the Collaboration on Quality Improvement Initiative for Achieving Excellence in Standards of COPD Care. <i>International Journal of COPD</i> , 2021, Volume 16, 2301-2322.	2.8	24
77	Racial Segregation and Respiratory Outcomes among Urban Black Residents with and at Risk of Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021, 204, 536-545.	12.2	30
78	Does Evaluation and Management of COPD Follow Therapeutic Strategy Recommendations?. <i>Chronic Obstructive Pulmonary Diseases (Miami, Fla )</i> , 2021, 8, 230-242.	0.9	5
79	InforMing the PATHway of COPD Treatment (IMPACT Trial) Single-Inhaler Triple Therapy (Fluticasone) Tj ETQq1 1 0.784314 rgBT /Over in Patients With COPD: Analysis of the Western Europe and North America Regions. <i>Chronic Obstructive Pulmonary Diseases (Miami, Fla )</i> , 2021, 8, 76-90.	0.9	1
80	Protocol Summary of the COPD Assessment in Primary Care To Identify Undiagnosed Respiratory Disease and Exacerbation Risk (CAPTURE) Validation in Primary Care Study. <i>Chronic Obstructive Pulmonary Diseases (Miami, Fla )</i> , 2021, 8, 60-75.	0.9	9
81	Improvements in lung function with budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler <i>versus</i> dual therapies in patients with COPD: a sub-study of the ETHOS trial. <i>Therapeutic Advances in Respiratory Disease</i> , 2021, 15, .	2.8	24
82	Epigenetic marker of telomeric age is associated with exacerbations and hospitalizations in chronic obstructive pulmonary disease. <i>Respiratory Research</i> , 2021, 22, .	4.5	11
83	The Effects of Rare <i>SERPINA1</i> Variants on Lung Function and Emphysema in SPIROMICS. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2020, 201, 540-554.	12.2	51
84	Association of Long-term Ambient Ozone Exposure With Respiratory Morbidity in Smokers. <i>JAMA Internal Medicine</i> , 2020, 180, 106.	10.8	67
85	Host, Gender, and Early-Life Factors as Risks for Chronic Obstructive Pulmonary Disease. <i>Clinics in Chest Medicine</i> , 2020, 41, 329-337.	3.6	10
86	Composite endpoints in COPD: clinically important deterioration in the UPLIFT trial. <i>Respiratory Research</i> , 2020, 21, .	4.5	22
87	Increased airway iron parameters and risk for exacerbation in COPD: an analysis from SPIROMICS. <i>Scientific Reports</i> , 2020, 10, .	3.5	26
88	Current smoking with or without chronic bronchitis is independently associated with goblet cell hyperplasia in healthy smokers and COPD subjects. <i>Scientific Reports</i> , 2020, 10, .	3.5	9
89	Progressive fibrosing interstitial lung disease: clinical uncertainties, consensus recommendations, and research priorities. <i>Lancet Respiratory Medicine</i> , the, 2020, 8, 925-934.	24.2	304
90	Identification of a unique temporal signature in blood and BAL associated with IPF progression. <i>Scientific Reports</i> , 2020, 10, .	3.5	15

#	ARTICLE	IF	PR CITATIONS
91	<p></p>Novel Respiratory Disability Score Predicts COPD Exacerbations and Mortality in the Spiromics Cohort</p>. International Journal of COPD, 2020, Volume 15, 1887-1898.	2.8	5
92	<p></p>Defining Chronic Mucus Hypersecretion Using the CAT in the SPIROMICS Cohort</p>. International Journal of COPD, 2020, Volume 15, 2467-2476.	2.8	15
93	Serum IgG Levels and Risk of COPD Hospitalization. Chest, 2020, 158, 1420-1430.	1.1	34
94	Efficacy and safety of two doses of budesonide/formoterol fumarate metered dose inhaler in COPD. ERJ Open Research, 2020, 6, 00187-2019.	2.6	7
95	Update in Interstitial Lung Disease 2019. American Journal of Respiratory and Critical Care Medicine, 2020, 202, 500-507.	12.2	30
96	Benefits of glycopyrrolate/formoterol fumarate metered dose inhaler (GFF MDI) in improving lung function and reducing exacerbations in patients with moderate-to-very severe COPD: a pooled analysis of the PINNACLE studies. Respiratory Research, 2020, 21, .	4.5	6
97	<p></p>FEV<sub>1</sub> is a stronger mortality predictor than FVC in patients with moderate COPD and with an increased risk for cardiovascular disease</p>. International Journal of COPD, 2020, Volume 15, 1135-1142.	2.8	58
98	Association of Dysanapsis With Chronic Obstructive Pulmonary Disease Among Older Adults. JAMA - Journal of the American Medical Association, 2020, 323, 2268.	17.1	173
99	Triple Inhaled Therapy at Two Glucocorticoid Doses in Moderate-to-Very-Severe COPD. New England Journal of Medicine, 2020, 383, 35-48.	43.7	528
100	Blood Eosinophil Counts in Clinical Trials for Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2020, 202, 660-671.	12.2	87
101	Reduction in All-Cause Mortality with Fluticasone Furoate/Umeclidinium/Vilanterol in Patients with Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2020, 201, 1508-1516.	12.2	214
102	Maintenance inhaler therapy preferences of patients with asthma or chronic obstructive pulmonary disease: a discrete choice experiment. Thorax, 2020, 75, 735-743.	5.8	26
103	The Effect of Inhaled Corticosteroid Withdrawal and Baseline Inhaled Treatment on Exacerbations in the IMPACT Study. A Randomized, Double-Blind, Multicenter Clinical Trial. American Journal of Respiratory and Critical Care Medicine, 2020, 202, 1237-1243.	12.2	37
104	A dose-ranging study of the inhaled dual phosphodiesterase 3 and 4 inhibitor ensifentrine in COPD. Respiratory Research, 2020, 21, .	4.5	56
105	A Systematically Derived Exposure Assessment Instrument for Chronic Hypersensitivity Pneumonitis. Chest, 2020, 157, 1506-1512.	1.1	51
106	<p></p>Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler Improves Lung Function versus Monotherapies in GOLD Category A Patients with COPD: Pooled Data from the Phase III PINNACLE Studies</p>. International Journal of COPD, 2020, Volume 15, 99-106.	2.8	3
107	Association of Guideline-Recommended COPD Inhaler Regimens With Mortality, Respiratory Exacerbations, and Quality of Life. Chest, 2020, 158, 529-538.	1.1	10
108	Randomised clinical trial to determine the safety of quercetin supplementation in patients with chronic obstructive pulmonary disease. BMJ Open Respiratory Research, 2020, 7, e000392.	2.6	104

#	ARTICLE	IF	PR CITATIONS
109	Pharmacologic Management of Chronic Obstructive Pulmonary Disease. An Official American Thoracic Society Clinical Practice Guideline. American Journal of Respiratory and Critical Care Medicine, 2020, 201, e56-e69.	12.2	266
110	The natural history of progressive fibrosing interstitial lung diseases. European Respiratory Journal, 2020, 55, 2000085.	12.1	224
111	Association of urine mitochondrial DNA with clinical measures of COPD in the SPIROMICS cohort. JCI Insight, 2020, 5, .	5.4	40
112	An airway epithelial IL-17A response signature identifies a steroid-unresponsive COPD patient subgroup. Journal of Clinical Investigation, 2019, 129, 169-181.	10.7	96
113	Voxel-Wise Longitudinal Parametric Response Mapping Analysis of Chest Computed Tomography in Smokers. Academic Radiology, 2019, 26, 217-223.	2.8	73
114	Clinical Approach to the Therapy of Asthma-COPD Overlap. Chest, 2019, 155, 168-177.	1.1	55
115	Computed Tomographic Biomarkers in Idiopathic Pulmonary Fibrosis. The Future of Quantitative Analysis. American Journal of Respiratory and Critical Care Medicine, 2019, 199, 12-21.	12.2	146
116	Serum amino acid concentrations and clinical outcomes in smokers: SPIROMICS metabolomics study. Scientific Reports, 2019, 9, .	3.5	28
117	Nintedanib and Sildenafil in Patients with Idiopathic Pulmonary Fibrosis and Right Heart Dysfunction. A Prespecified Subgroup Analysis of a Double-Blind Randomized Clinical Trial (INSTAGE). American Journal of Respiratory and Critical Care Medicine, 2019, 200, 1505-1512.	12.2	58
118	Imaging-based clusters in former smokers of the COPD cohort associate with clinical characteristics: the SubPopulations and intermediate outcome measures in COPD study (SPIROMICS). Respiratory Research, 2019, 20, .	4.5	33
119	Blood eosinophils and treatment response with triple and dual combination therapy in chronic obstructive pulmonary disease: analysis of the IMPACT trial. Lancet Respiratory Medicine, the, 2019, 7, 745-756.	24.2	202
120	Diagnostic Likelihood Thresholds That Define a Working Diagnosis of Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2019, 200, 1146-1153.	12.2	68
121	Metoprolol for the Prevention of Acute Exacerbations of COPD. New England Journal of Medicine, 2019, 381, 2304-2314.	43.7	156
122	Low Dose Carbon Monoxide Exposure in Idiopathic Pulmonary Fibrosis Produces a CO Signature Comprised of Oxidative Phosphorylation Genes. Scientific Reports, 2019, 9, .	3.5	16
123	Riociguat for idiopathic interstitial pneumonia-associated pulmonary hypertension (RISE-IIP): a randomised, placebo-controlled phase 2b study. Lancet Respiratory Medicine, the, 2019, 7, 780-790.	24.2	217
124	A phase III study of triple therapy with budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler 320/18/9.6µg and 160/18/9.6µg using co-suspension delivery technology in moderate-to-very severe COPD: The ETHOS study protocol. Respiratory Medicine, 2019, 158, 59-66.	22.8	35
125	Spirometric indices of early airflow impairment in individuals at risk of developing COPD: Spirometry beyond FEV1/FVC. Respiratory Medicine, 2019, 156, 58-68.	2.8	64
126	Serum biomarkers and outcomes in patients with moderate COPD: a substudy of the randomised SUMMIT trial. BMJ Open Respiratory Research, 2019, 6, e000431.	2.6	35

#	ARTICLE	IF	PR CITATIONS
127	Inference of Cellular Immune Environments in Sputum and Peripheral Blood Associated with Acute Exacerbations of COPD. Cellular and Molecular Bioengineering, 2019, 12, 165-177.	1.9	5
128	Diagnosis and management of asthma, COPD and asthmaâ€COPD overlap among primary care physicians and respiratory/allergy specialists: A global survey. Clinical Respiratory Journal, 2019, 13, 355-367.	2.2	12
129	Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease: the GOLD science committee report 2019. European Respiratory Journal, 2019, 53, 1900164.	12.1	1,584
130	A Genetic Risk Score Associated with Chronic Obstructive Pulmonary Disease Susceptibility and Lung Structure on Computed Tomography. American Journal of Respiratory and Critical Care Medicine, 2019, 200, 721-731.	12.2	46
131	Increased monocyte count as a cellular biomarker for poor outcomes in fibrotic diseases: a retrospective, multicentre cohort study. Lancet Respiratory Medicine, the, 2019, 7, 497-508.	24.2	223
132	Use of a molecular classifier to identify usual interstitial pneumonia in conventional transbronchial lung biopsy samples: a prospective validation study. Lancet Respiratory Medicine, the, 2019, 7, 487-496.	24.2	150
133	The characterisation of interstitial lung disease multidisciplinary team meetings: A global study. ERJ Open Research, 2019, 5, 00209-2018.	2.6	67
134	Noninvasive Imaging Biomarker Identifies Small Airway Damage in Severe Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2019, 200, 575-581.	12.2	147
135	Systemic Markers of Inflammation in Smokers With Symptoms Despite Preserved Spirometry in SPIROMICS. Chest, 2019, 155, 908-917.	1.1	25
136	Reprint of: Voxel-Wise Longitudinal Parametric Response Mapping Analysis of Chest Computed Tomography in Smokers. Academic Radiology, 2019, 26, 306-312.	2.8	13
137	Lung Microbiota Contribute to Pulmonary Inflammation and Disease Progression in Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2019, 199, 1127-1138.	12.2	314
138	Itâ€™s difficult, itâ€™s life changing what happens to youâ€™ patient perspective on life with chronic hypersensitivity pneumonitis: a qualitative study. BMJ Open Respiratory Research, 2019, 6, e000522.	2.6	16
139	Relationship between diffusion capacity and small airway abnormality in COPD Gene. Respiratory Research, 2019, 20, .	4.5	34
140	Alignment of Inhaled Chronic Obstructive Pulmonary Disease Therapies with Published Strategies. Analysis of the Global Initiative for Chronic Obstructive Lung Disease Recommendations in SPIROMICS. Annals of the American Thoracic Society, 2019, 16, 200-208.	3.8	39
141	Why Does an Aging Smokerâ€™s Lung Develop Idiopathic Pulmonary Fibrosis and Not Chronic Obstructive Pulmonary Disease?. American Journal of Respiratory and Critical Care Medicine, 2019, 199, 279-285.	12.2	29
142	Telomere Length and Use of Immunosuppressive Medications in Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2019, 200, 336-347.	12.2	150
143	Effects of baseline symptom burden on treatment response in COPD. International Journal of COPD, 2019, Volume 14, 181-194.	2.8	8
144	Current Controversies in Chronic Obstructive Pulmonary Disease. A Report from the Global Initiative for Chronic Obstructive Lung Disease Scientific Committee. Annals of the American Thoracic Society, 2019, 16, 29-39.	3.8	17

#	ARTICLE	IF	PR CITATIONS
145	Closing the Evidence Gap in Interstitial Lung Disease. The Promise of Real-World Data. American Journal of Respiratory and Critical Care Medicine, 2019, 199, 1061-1065.	12.2	10
146	Safety and Tolerability of Comprehensive Research Bronchoscopy in Chronic Obstructive Pulmonary Disease. Results from the SPIROMICS Bronchoscopy Substudy. Annals of the American Thoracic Society, 2019, 16, 439-446.	3.8	26
147	Hypersensitivity Pneumonitis. Chest, 2019, 155, 699-711.	1.1	198
148	Pulmonary hypertension in chronic lung disease and hypoxia. European Respiratory Journal, 2019, 53, 1801914.	12.1	625
149	Mortality and Exacerbations by Global Initiative for Chronic Obstructive Lung Disease Groups ABCD: 2011 Versus 2017 in the COPDGene® Cohort. Chronic Obstructive Pulmonary Diseases (Miami, Fla ), 2019, 6, 64-73.	0.9	28
150	COPDGene® 2019: Redefining the Diagnosis of Chronic Obstructive Pulmonary Disease. Chronic Obstructive Pulmonary Diseases (Miami, Fla ), 2019, 6, 384-399.	0.9	139
151	β <sub>2</sub> -Blocker Therapy and Clinical Outcomes in Patients with Moderate Chronic Obstructive Pulmonary Disease and Heightened Cardiovascular Risk. An Observational Substudy of SUMMIT. Annals of the American Thoracic Society, 2018, 15, 608-614.	3.8	25
152	Patient-reported Outcomes for the Detection, Quantification, and Evaluation of Chronic Obstructive Pulmonary Disease Exacerbations. American Journal of Respiratory and Critical Care Medicine, 2018, 198, 730-738.	12.2	32
153	Update in Chronic Obstructive Pulmonary Disease 2017. American Journal of Respiratory and Critical Care Medicine, 2018, 197, 1534-1539.	12.2	3
154	Once-Daily Single-Inhaler Triple versus Dual Therapy in Patients with COPD. New England Journal of Medicine, 2018, 378, 1671-1680.	43.7	1,065
155	Exacerbations of Chronic Obstructive Pulmonary Disease and Cardiac Events. A Post Hoc Cohort Analysis from the SUMMIT Randomized Clinical Trial. American Journal of Respiratory and Critical Care Medicine, 2018, 198, 51-57.	12.2	307
156	Human airway branch variation and chronic obstructive pulmonary disease. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, .	7.6	108
157	At the Root: Defining and Halting Progression of Early Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2018, 197, 1540-1551.	12.2	254
158	Efficacy and safety profile of xanthines in COPD: a network meta-analysis. European Respiratory Review, 2018, 27, 180010.	8.7	45
159	Serum IgG subclass levels and risk of exacerbations and hospitalizations in patients with COPD. Respiratory Research, 2018, 19, .	4.5	44
160	Rural Residence and Chronic Obstructive Pulmonary Disease Exacerbations. Analysis of the SPIROMICS Cohort. Annals of the American Thoracic Society, 2018, 15, 808-816.	3.8	40
161	Alveolar eosinophilia in current smokers with chronic obstructive pulmonary disease in the SPIROMICS cohort. Journal of Allergy and Clinical Immunology, 2018, 141, 429-432.	6.2	20
162	Identification of Diagnostic Criteria for Chronic Hypersensitivity Pneumonitis. An International Modified Delphi Survey. American Journal of Respiratory and Critical Care Medicine, 2018, 197, 1036-1044.	12.2	197

#	ARTICLE	IF	PR CITATIONS
163	A Phase II Clinical Trial of Low-Dose Inhaled Carbon Monoxide in Idiopathic Pulmonary Fibrosis. <i>Chest</i> , 2018, 153, 94-104.	1.1	90
164	Centrilobular emphysema and coronary artery calcification: mediation analysis in the SPIROMICS cohort. <i>Respiratory Research</i> , 2018, 19, .	4.5	28
165	Heterogeneous burden of lung disease in smokers with borderline airflow obstruction. <i>Respiratory Research</i> , 2018, 19, .	4.5	12
166	Confronting the Challenge of COPD. <i>Chest</i> , 2018, 154, 984-985.	1.1	9
167	Imaging-based clusters in current smokers of the COPD cohort associate with clinical characteristics: the SubPopulations and Intermediate Outcome Measures in COPD Study (SPIROMICS). <i>Respiratory Research</i> , 2018, 19, .	4.5	23
168	Focus on Idiopathic Pulmonary Fibrosis. <i>Chest</i> , 2018, 154, 978-979.	1.1	14
169	Triple therapy with budesonide/glycopyrrolate/formoterol fumarate with co-suspension delivery technology versus dual therapies in chronic obstructive pulmonary disease (KRONOS): a double-blind, parallel-group, multicentre, phase 3 randomised controlled trial. <i>Lancet Respiratory Medicine</i> , 2018, 6, 747-758.	24.2	320
170	Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2018, 198, e44-e68.	12.2	3,529
171	Determinants of Response to Roflumilast in Severe Chronic Obstructive Pulmonary Disease. Pooled Analysis of Two Randomized Trials. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2018, 198, 1268-1278.	12.2	66
172	Development and validation of a radiological diagnosis model for hypersensitivity pneumonitis. <i>European Respiratory Journal</i> , 2018, 52, 1800443.	12.1	69
173	Genome-wide association study of lung function and clinical implication in heavy smokers. <i>BMC Medical Genetics</i> , 2018, 19, .	2.0	36
174	Precision medicine in COPD: where are we and where do we need to go?. <i>European Respiratory Review</i> , 2018, 27, 180022.	8.7	76
175	Relationship of Absolute Telomere Length With Quality of Life, Exacerbations, and Mortality in COPD. <i>Chest</i> , 2018, 154, 266-273.	1.1	25
176	Cardiac Troponin I and Cardiovascular Risk in Patients With Chronic Obstructive Pulmonary Disease. <i>Journal of the American College of Cardiology</i> , 2018, 72, 1126-1137.	2.4	61
177	Blood pressure, heart rate, and mortality in chronic obstructive pulmonary disease: the SUMMIT trial. <i>European Heart Journal</i> , 2018, 39, 3128-3134.	2.3	47
178	Can CAPTURE be used to identify undiagnosed patients with mild-to-moderate COPD likely to benefit from treatment?. <i>International Journal of COPD</i> , 2018, Volume 13, 1901-1912.	2.8	14
179	Laparoscopic anti-reflux surgery for the treatment of idiopathic pulmonary fibrosis (WRAP-IPF): a multicentre, randomised, controlled phase 2 trial. <i>Lancet Respiratory Medicine</i> , 2018, 6, 707-714.	24.2	129
180	Chronic obstructive pulmonary disease subpopulations and phenotyping. <i>Journal of Allergy and Clinical Immunology</i> , 2018, 141, 1961-1971.	6.2	71

#	ARTICLE	IF	PR CITATIONS
181	NT-proBNP in stable COPD and future exacerbation risk: Analysis of the SPIROMICS cohort. <i>Respiratory Medicine</i> , 2018, 140, 87-93.	2.8	26
182	Elevated circulating MMP-9 is linked to increased COPD exacerbation risk in SPIROMICS and COPD Gene. <i>JCI Insight</i> , 2018, 3, .	5.4	68
183	A randomized, seven-day study to assess the efficacy and safety of a glycopyrrolate/formoterol fumarate fixed-dose combination metered dose inhaler using novel Co-Suspension <sup>®</sup> , <sup>®</sup> Delivery Technology in patients with moderate-to-very severe chronic obstructive pulmonary disease. <i>Respiratory Research</i> , 2017, 18, .	4.5	22
184	Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Lung Disease 2017 Report. <i>Respirology</i> , 2017, 22, 575-601.	4.1	321
185	Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report: GOLD Executive Summary. <i>European Respiratory Journal</i> , 2017, 49, 1700214.	12.1	601
186	Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report. GOLD Executive Summary. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2017, 195, 557-582.	12.2	2,742
187	Microbes Are Associated with Host Innate Immune Response in Idiopathic Pulmonary Fibrosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2017, 196, 208-219.	12.2	148
188	GDF-15 plasma levels in chronic obstructive pulmonary disease are associated with subclinical coronary artery disease. <i>Respiratory Research</i> , 2017, 18, .	4.5	32
189	Cardiovascular outcomes with an inhaled beta2-agonist/corticosteroid in patients with COPD at high cardiovascular risk. <i>Heart</i> , 2017, 103, 1536-1542.	4.3	46
190	A Standardized Diagnostic Ontology for Fibrotic Interstitial Lung Disease. An International Working Group Perspective. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2017, 196, 1249-1254.	12.2	206
191	Comprehensive and Individualized Patient Care in Idiopathic Pulmonary Fibrosis. <i>Chest</i> , 2017, 151, 1173-1174.	1.1	14
192	Serum IgG and risk of exacerbations and hospitalizations in chronic obstructive pulmonary disease. <i>Journal of Allergy and Clinical Immunology</i> , 2017, 140, 1164-1167.e6.	6.2	38
193	Respiratory Symptoms Items from the COPD Assessment Test Identify Ever-Smokers with Preserved Lung Function at Higher Risk for Poor Respiratory Outcomes. An Analysis of the Subpopulations and Intermediate Outcome Measures in COPD Study Cohort. <i>Annals of the American Thoracic Society</i> , 2017, 14, 636-642.	3.8	32
194	The peripheral blood proteome signature of idiopathic pulmonary fibrosis is distinct from normal and is associated with novel immunological processes. <i>Scientific Reports</i> , 2017, 7, .	3.5	56
195	Efficacy and Safety of Glycopyrrolate/Formoterol Metered Dose Inhaler Formulated Using Co-Suspension Delivery Technology in Patients With COPD. <i>Chest</i> , 2017, 151, 340-357.	1.1	99
196	Informe 2017 de la Iniciativa Global para el Diagnóstico, Tratamiento y Prevención de la Enfermedad Pulmonar Obstructiva Crónica: Resumen Ejecutivo de GOLD. <i>Archivos De Bronconeumología</i> , 2017, 53, 128-149.	1.5	331
197	The diagnosis of idiopathic pulmonary fibrosis: current and future approaches. <i>Lancet Respiratory Medicine</i> , 2017, 5, 61-71.	24.2	99
198	Efficacy of simtuzumab versus placebo in patients with idiopathic pulmonary fibrosis: a randomised, double-blind, controlled, phase 2 trial. <i>Lancet Respiratory Medicine</i> , 2017, 5, 22-32.	24.2	247

#	ARTICLE	IF	PR CITATIONS
199	Diagnosis and Treatment of Fibrotic Hypersensitivity Pneumonia. Where We Stand and Where We Need to Go. American Journal of Respiratory and Critical Care Medicine, 2017, 196, 690-699.	12.2	210
200	Design of the Subpopulations and Intermediate Outcome Measures in COPD (SPIROMICS) AIR Study. BMJ Open Respiratory Research, 2017, 4, e000186.	2.6	24
201	Idiopathic pulmonary fibrosis. Nature Reviews Disease Primers, 2017, 3, .	50.7	1,179
202	Targeting the vascular and perivascular niches as a regenerative therapy for lung and liver fibrosis. Science Translational Medicine, 2017, 9, .	12.7	107
203	Diagnostic accuracy of a clinical diagnosis of idiopathic pulmonary fibrosis: an international caseâ€“cohort study. European Respiratory Journal, 2017, 50, 1700936.	12.1	90
204	Possible UIP pattern on high-resolution computed tomography is associated with better survival than definite UIP in IPF patients. Respiratory Medicine, 2017, 131, 229-235.	2.8	30
205	Baseline Symptom Score Impact on Benefits of Glycopyrrolate/Formoterol Metered Dose Inhaler in COPD. Chest, 2017, 152, 1169-1178.	1.1	37
206	Pneumonia risk with inhaled fluticasone furoate and vilanterol in COPD patients with moderate airflow limitation: The SUMMIT trial. Respiratory Medicine, 2017, 131, 27-34.	2.8	32
207	Association of sputum and blood eosinophil concentrations with clinical measures of COPD severity: an analysis of the SPIROMICS cohort. Lancet Respiratory Medicine,the, 2017, 5, 956-967.	24.2	276
208	Usual Interstitial Pneumonia Can Be Detected in Transbronchial Biopsies Using Machine Learning. Annals of the American Thoracic Society, 2017, 14, 1646-1654.	3.8	86
209	Frequency of exacerbations in patients with chronic obstructive pulmonary disease: an analysis of the SPIROMICS cohort. Lancet Respiratory Medicine,the, 2017, 5, 619-626.	24.2	276
210	Azithromycin and risk of COPD exacerbations in patients with and without Helicobacter pylori. Respiratory Research, 2017, 18, .	4.5	7
211	Effect of beta-blockers on exacerbation rate and lung function in chronic obstructive pulmonary disease (COPD). Respiratory Research, 2017, 18, .	4.5	33
212	The Role of Chest Computed Tomography in the Evaluation and Management of the Patient with Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2017, 196, 1372-1379.	12.2	132
213	Idiopathic Pulmonary Fibrosis: The Association between the Adaptive Multiple Features Method and Fibrosis Outcomes. American Journal of Respiratory and Critical Care Medicine, 2017, 195, 921-929.	12.2	127
214	Effect of Fluticasone Furoate and Vilanterol on Exacerbations of Chronic Obstructive Pulmonary Disease in Patients with Moderate Airflow Obstruction. American Journal of Respiratory and Critical Care Medicine, 2017, 195, 881-888.	12.2	51
215	A New Approach for Identifying Patients with Undiagnosed Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2017, 195, 748-756.	12.2	134
216	Biomarkers Predictive of Exacerbations in the SPIROMICS and COPD Gene Cohorts. American Journal of Respiratory and Critical Care Medicine, 2017, 195, 473-481.	12.2	115

#	ARTICLE	IF	PR CITATIONS
217	Chronic Respiratory Symptoms with Normal Spirometry. A Reliable Clinical Entity?. American Journal of Respiratory and Critical Care Medicine, 2017, 195, 17-22.	12.2	47
218	Variability in objective and subjective measures affects baseline values in studies of patients with COPD. PLoS ONE, 2017, 12, e0184606.	2.4	27
219	Guiding Principles for the Use of Nebulized Long-Acting Beta2-Agonists in Patients with COPD: An Expert Panel Consensus. Chronic Obstructive Pulmonary Diseases (Miami, Fla ), 2017, 4, 7-20.	0.9	10
220	Efficacy of Formoterol Fumarate Delivered by Metered Dose Inhaler Using Co-Suspension <sup>®</sup> , <sup>†</sup> Delivery Technology Versus Foradil <sup>®</sup> Aerolizer <sup>®</sup> in Moderate-To-Severe COPD: A Randomized, Dose-Ranging Study. Chronic Obstructive Pulmonary Diseases (Miami, Fla ), 2017, 4, 21-33.	0.9	5
221	Correcting Nonpathological Variation in Longitudinal Parametric Response Maps of CT Scans in COPD Subjects: SPIROMICS. Tomography, 2017, 3, 138-145.	2.0	4
222	Effects of roflumilast in COPD patients receiving inhaled corticosteroid/long-acting $\beta_2$ -agonist fixed-dose combination: Rationale and study design. International Journal of COPD, 2016, Volume 11, 1921-1928.	2.8	11
223	Insight into Best Variables for COPD Case Identification: A Random Forests Analysis. Chronic Obstructive Pulmonary Diseases (Miami, Fla ), 2016, 3, 406-418.	0.9	15
224	Understanding the impact of second-hand smoke exposure on clinical outcomes in participants with COPD in the SPIROMICS cohort. Thorax, 2016, 71, 411-420.	5.8	26
225	Age-Related Differences in Health-Related Quality of Life in COPD. Chest, 2016, 149, 927-935.	1.1	49
226	Integrated Genomics Reveals Convergent Transcriptomic Networks Underlying Chronic Obstructive Pulmonary Disease and Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2016, 194, 948-960.	12.2	120
227	Plasma Surfactant Protein-D, Matrix Metalloproteinase-7, and Osteopontin Index Distinguishes Idiopathic Pulmonary Fibrosis from Other Idiopathic Interstitial Pneumonias. American Journal of Respiratory and Critical Care Medicine, 2016, 194, 1242-1251.	12.2	163
228	Clinical Significance of Symptoms in Smokers with Preserved Pulmonary Function. New England Journal of Medicine, 2016, 374, 1811-1821.	43.7	625
229	A multicenter, randomized, double-blind dose-ranging study of glycopyrrolate/formoterol fumarate fixed-dose combination metered dose inhaler compared to the monocomponents and open-label tiotropium dry powder inhaler in patients with moderate-to-severe COPD. Respiratory Medicine, 2016, 120, 16-24.	2.8	19
230	Predictors of idiopathic pulmonary fibrosis in absence of radiologic honeycombing: A cross sectional analysis in ILD patients undergoing lung tissue sampling. Respiratory Medicine, 2016, 118, 88-95.	2.8	46
231	SPIROMICS Protocol for Multicenter Quantitative Computed Tomography to Phenotype the Lungs. American Journal of Respiratory and Critical Care Medicine, 2016, 194, 794-806.	12.2	232
232	Current Controversies in the Pharmacological Treatment of Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2016, 194, 541-549.	12.2	76
233	Development of the chronic obstructive pulmonary disease morning symptom diary (COPD-MSD). Health and Quality of Life Outcomes, 2016, 14, .	3.0	9
234	Meeting the challenge of COPD care delivery in the USA: a multiprovider perspective. Lancet Respiratory Medicine, 2016, 4, 473-526.	24.2	90

#	ARTICLE	IF	PR CITATIONS
235	Acute Exacerbation of Idiopathic Pulmonary Fibrosis. An International Working Group Report. American Journal of Respiratory and Critical Care Medicine, 2016, 194, 265-275.	12.2	1,248
236	Idiopathic Pulmonary Fibrosis. Chest, 2016, 149, 491-498.	1.1	96
237	Association between Functional Small Airway Disease and FEV <sub>1</sub> Decline in Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2016, 194, 178-184.	12.2	366
238	The Microbiome and the Respiratory Tract. Annual Review of Physiology, 2016, 78, 481-504.	17.2	814
239	Common Genetic Polymorphisms Influence Blood Biomarker Measurements in COPD. PLoS Genetics, 2016, 12, e1006011.	3.3	95
240	Six-SOMAmer Index Relating to Immune, Protease and Angiogenic Functions Predicts Progression in IPF. PLoS ONE, 2016, 11, e0159878.	2.4	50
241	The Human Microbiome in the Lung: Are Infections Contributing to Lung Health and Disease?. Chronic Obstructive Pulmonary Diseases (Miami, Fla ), 2016, 3, 466-472.	0.9	11
242	Integrative phenotyping framework (iPF): integrative clustering of multiple omics data identifies novel lung disease subphenotypes. BMC Genomics, 2015, 16, .	3.3	99
243	Identifying cases of undiagnosed, clinically significant COPD in primary care: qualitative insight from patients in the target population. Npj Primary Care Respiratory Medicine, 2015, 25, .	4.3	15
244	Acute exacerbations of chronic obstructive pulmonary disease are associated with decreased CD4+ & CD8+ T cells and increased growth & differentiation factor-15 (GDF-15) in peripheral blood. Respiratory Research, 2015, 16, .	4.5	55
245	The Impact of Sources of Variability on Parametric Response Mapping of Lung CT Scans. Tomography, 2015, 1, 69-77.	2.0	27
246	Parametric Response Mapping Monitors Temporal Changes on Lung CT Scans in the Subpopulations and Intermediate Outcome Measures in COPD Study (SPIROMICS). Academic Radiology, 2015, 22, 186-194.	2.8	100
247	Effect of roflumilast on exacerbations in patients with severe chronic obstructive pulmonary disease uncontrolled by combination therapy (REACT): a multicentre randomised controlled trial. Lancet, The, 2015, 385, 857-866.	52.8	339
248	Pneumonia Risk with Inhaled Fluticasone Furoate and Vilanterol Compared with Vilanterol Alone in Patients with COPD. Annals of the American Thoracic Society, 2015, 12, 27-34.	3.8	142
249	An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis. An Update of the 2011 Clinical Practice Guideline. American Journal of Respiratory and Critical Care Medicine, 2015, 192, e3-e19.	12.2	1,718
250	Association of hospital admission and forced vital capacity endpoints with survival in patients with idiopathic pulmonary fibrosis: analysis of a pooled cohort from three clinical trials. Lancet Respiratory Medicine, the, 2015, 3, 388-396.	24.2	77
251	Current concepts in targeting chronic obstructive pulmonary disease pharmacotherapy: making progress towards personalised management. Lancet, The, 2015, 385, 1789-1798.	52.8	226
252	A new era in idiopathic pulmonary fibrosis: considerations for future clinical trials. European Respiratory Journal, 2015, 46, 243-249.	12.1	51

#	ARTICLE	IF	PR CITATIONS
253	Heart Failure and Respiratory Hospitalizations Are Reduced in Patients With Heart Failure and Chronic Obstructive Pulmonary Disease With the Use of an Implantable Pulmonary Artery Pressure Monitoring Device. <i>Journal of Cardiac Failure</i> , 2015, 21, 240-249.	1.9	54
254	CC-chemokine ligand 2 inhibition in idiopathic pulmonary fibrosis: a phase 2 trial of carlumab. <i>European Respiratory Journal</i> , 2015, 46, 1740-1750.	12.1	130
255	<i>TOLLIP</i>, <i>MUC5B</i>, and the Response to <i>N</i>-Acetylcysteine among Individuals with Idiopathic Pulmonary Fibrosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2015, 192, 1475-1482.	12.2	304
256	Older Adults with Chronic Lung Disease Report Less Limitation Compared with Younger Adults with Similar Lung Function Impairment. <i>Annals of the American Thoracic Society</i> , 2015, 12, 21-26.	3.8	21
257	Basal Gene Expression by Lung CD4+ T Cells in Chronic Obstructive Pulmonary Disease Identifies Independent Molecular Correlates of Airflow Obstruction and Emphysema Extent. <i>PLoS ONE</i> , 2014, 9, e96421.	2.4	24
258	Human CD56+ Cytotoxic Lung Lymphocytes Kill Autologous Lung Cells in Chronic Obstructive Pulmonary Disease. <i>PLoS ONE</i> , 2014, 9, e103840.	2.4	55
259	Inflammatory Leukocyte Phenotypes Correlate with Disease Progression in Idiopathic Pulmonary Fibrosis. <i>Frontiers in Medicine</i> , 2014, 1, .	2.6	51
260	Design of the Subpopulations and Intermediate Outcomes in COPD Study (SPIROMICS): TableÂ1. <i>Thorax</i> , 2014, 69, 492-495.	5.8	346
261	Cell-associated bacteria in the human lung microbiome. <i>Microbiome</i> , 2014, 2, .	11.5	71
262	Smoking-related idiopathic interstitial pneumonia. <i>European Respiratory Journal</i> , 2014, 44, 594-602.	12.1	39
263	Analysis of Culture-Dependent versus Culture-Independent Techniques for Identification of Bacteria in Clinically Obtained Bronchoalveolar Lavage Fluid. <i>Journal of Clinical Microbiology</i> , 2014, 52, 3605-3613.	4.1	157
264	The role of the microbiome in exacerbations of chronic lung diseases. <i>Lancet, The</i> , 2014, 384, 691-702.	52.8	446
265	Study Design Implications of Death and Hospitalization as End Points in Idiopathic Pulmonary Fibrosis. <i>Chest</i> , 2014, 146, 1256-1262.	1.1	29
266	Changes in the Lung Microbiome following Lung Transplantation Include the Emergence of Two Distinct <i>Pseudomonas</i> Species with Distinct Clinical Associations. <i>PLoS ONE</i> , 2014, 9, e97214.	2.4	174
267	Identifying Patients with Undiagnosed COPD in Primary Care Settings: Insight from Screening Tools and Epidemiologic Studies. <i>Chronic Obstructive Pulmonary Diseases (Miami, Fla )</i> , 2014, 2, 103-121.	0.9	41
268	Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2013, 187, 347-365.	12.2	7,074
269	Anti-acid treatment and disease progression in idiopathic pulmonary fibrosis: an analysis of data from three randomised controlled trials. <i>Lancet Respiratory Medicine,the</i> , 2013, 1, 369-376.	24.2	369
270	Treatment of Idiopathic Pulmonary Fibrosis With Ambrisentan. <i>Annals of Internal Medicine</i> , 2013, 158, 641.	10.4	512

#	ARTICLE	IF	PR CITATIONS
271	MMP Mediated Degradation of Type IV Collagen Alpha 1 and Alpha 3 Chains Reflects Basement Membrane Remodeling in Experimental and Clinical Fibrosis – Validation of Two Novel Biomarker Assays. PLoS ONE, 2013, 8, e84934.	2.4	168
272	An Assessment of Epithelial and Mesenchymal Phenotypes in Experimental and Clinical Pulmonary Fibrosis. ISRN Pulmonology, 2012, 2012, 1-11.	0.5	0
273	Relationship Between Lung Function Impairment and Health-Related Quality of Life in COPD and Interstitial Lung Disease. Chest, 2012, 142, 704-711.	1.1	32
274	Prednisone, Azathioprine, and N-Acetylcysteine for Pulmonary Fibrosis. New England Journal of Medicine, 2012, 366, 1968-1977.	43.7	1,533
275	The future of chronic obstructive pulmonary disease treatment – difficulties of and barriers to drug development. Lancet, The, 2011, 378, 1027-1037.	52.8	87
276	Diagnosis, Assessment, and Treatment of Non-Pulmonary Arterial Hypertension Pulmonary Hypertension. Journal of the American College of Cardiology, 2009, 54, S85-S96.	2.4	357
277	Development and Initial Validation of a Self-Scored COPD Population Screener Questionnaire (COPD-PS). COPD: Journal of Chronic Obstructive Pulmonary Disease, 2008, 5, 85-95.	2.1	227
278	Accuracy of High-Resolution CT in the Diagnosis of Diffuse Lung Disease: Effect of Predominance and Distribution of Findings. American Journal of Roentgenology, 2008, 191, 1032-1039.	4.2	72
279	Sex Differences in Severe Pulmonary Emphysema. American Journal of Respiratory and Critical Care Medicine, 2007, 176, 243-252.	12.2	331
280	Predictors of Mortality in Patients with Emphysema and Severe Airflow Obstruction. American Journal of Respiratory and Critical Care Medicine, 2006, 173, 1326-1334.	12.2	409
281	Is it asthma or COPD?. Postgraduate Medicine, 2005, 117, 19-26.	2.8	27
282	Surgical Therapy for Chronic Obstructive Pulmonary Disease. Seminars in Respiratory and Critical Care Medicine, 2005, 26, 167-191.	2.4	45
283	Acute exacerbation of chronic bronchitis: expanding short-course therapy. International Journal of Antimicrobial Agents, 2005, 26, S156-S163.	4.0	6
284	Idiopathic Interstitial Pneumonia. American Journal of Respiratory and Critical Care Medicine, 2004, 170, 904-910.	12.2	616
285	Acute bronchitis: State of the art diagnosis and therapy. Comprehensive Therapy, 2004, 30, 55-69.	0.3	16
286	Patient selection for lung volume reduction surgery. Chest Surgery Clinics of North America, 2003, 13, 669-685.	1.4	8
287	Diagnosing chronic obstructive pulmonary disease. Postgraduate Medicine, 1998, 103, 112-125.	2.8	16
288	Use of a Genomic Classifier in Patients with Interstitial Lung Disease: A Systematic Review. Annals of the American Thoracic Society, 0, , .	3.8	14

#	ARTICLE	IF	PR CITATIONS
289	Research priorities to address the global burden of chronic obstructive pulmonary disease (COPD) in the next decade. <i>Journal of Global Health</i> , 0, 11, .	2.9	38
290	Higher COPD Assessment Test Score Associated With Greater Exacerbations Risk: A Post Hoc Analysis of the IMPACT Trial. <i>Chronic Obstructive Pulmonary Diseases (Miami, Fla )</i> , 0, , .	0.9	7
291	Characterizing COPD Symptom Variability in the Stable State Utilizing the Evaluating Respiratory Symptoms in COPD Questionnaire. <i>Chronic Obstructive Pulmonary Diseases (Miami, Fla )</i> , 0, , .	0.9	1